title: Timing of growth hormone treatment affects trabecular bone microarchitecture and mineralization in growth hormone deficient mice.
abstract: Growth hormone (GH) is essential in the development of bone mass, and a growth hormone deficiency (GHD) in childhood is frequently treated with daily injections of GH. It is not clear what effect GHD and its treatment has on bone. It was hypothesized that GHD would result in impaired microarchitecture, and an early onset of treatment would result in a better recovery than late onset. Growth hormone deficient homozygous (lit/lit) mice of both sexes were divided into two treatment groups receiving daily injections of GH, starting at an early (21 days of age) or a late time point (35 days of age, corresponding to the end of puberty). A group of heterozygous mice with normal levels of growth hormone served as controls. In vivo micro-computed tomography scans of the fourth lumbar vertebra were obtained at five time points between 21 and 60 days of age, and trabecular morphology and volumetric BMD were analyzed to determine the effects of GH on bone microarchitecture. Early GH treatment led to significant improvements in bone volume ratio (p=0.006), tissue mineral density (p=0.005), and structure model index (p=0.004) by the study endpoint (day 60), with no detected change in trabecular thickness. Trabecular number increased and trabecular separation decreased in GHD mice regardless of treatment compared to heterozygous mice. This suggests fundamental differences in the structure of trabecular bone in GHD and GH treated mice, reflected by an increased number of thinner trabeculae in these mice compared to heterozygous controls. There were no significant differences between the late treatment group and GHD mice except for connectivity density. Taken together, these results indicate that bone responds to GH treatment initiated before puberty but not to treatment commencing post-puberty, and that GH treatment does not rescue the structure of trabecular bone to that of heterozygous controls.
authors.affiliation: Department of Mechanical and Manufacturing Engineering, Schulich School of Engineering, University of Calgary, Calgary, Canada. ekristensen@gmail.com
authors.forename: Erika
authors.initials: E
authors.lastname: Kristensen
authors.forename: Benedikt
authors.initials: B
authors.lastname: Hallgrímsson
authors.forename: Douglas W
authors.initials: DW
authors.lastname: Morck
authors.forename: Steven K
authors.initials: SK
authors.lastname: Boyd
mesh_terms: D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects* / Q000473:pathology*; D002113:Calcification, Physiologic / Q000187:drug effects*; D013006:Growth Hormone / Q000008:administration & dosage / Q000172:deficiency* / Q000378:metabolism / Q000494:pharmacology*; D006720:Homozygote; D051379:Mice; D016011:Normal Distribution; D009929:Organ Size / Q000187:drug effects; D013997:Time Factors
chemical_list: D013006:Growth Hormone